December 12, 2024

Innovation Prize 2025 of the German BioRegions – Application Deadline: February 14, 2025

Innovation Prize 2025 of the German BioRegions – Application Deadline: February 14, 2025

Innovators wanted. APPLY NOW!
WE SUPPORT YOUR INNOVATIVE INVENTION!

The work group of the BioRegions in Germany is the central network of regional initiatives promoting the economic use of modern biotechnologies in Germany. It annually awards the Innovation Prize of the BioRegions in Germany. This year, the work group again recognizes application-oriented ideas with strong implementation potential and showcases them at the German Biotech Days.

What is awarded?

  • The Innovation Prize honors innovative ideas that are patented or have been submitted for patenting.
  • We seek application-oriented ideas with strong implementation potential and high market opportunities.
  • Our aim is to support outstanding innovations that can significantly contribute to the economy and society.

Who can apply?

  • Scientists from universities and non-university institutions
  • Legal entities under public law, such as universities, universities of applied sciences, or patent exploitation agencies
  • Founders of companies that have not yet generated significant revenue and have not transferred substantial company shares to external investors

What do we offer?

  • Invitation for six finalists to the German Biotech Days on April 9 and 10, 2025, in Heidelberg
  • Presentation to an international audience, financiers, and the trade press
  • Three awards, each worth €2,000
  • An audience award worth €2,000

Apply now!

Application Deadline: February 14, 2025.


Our latest News

discover more
New bioRN Members of 2025

New bioRN Members of 2025

In 2025, the bioRN cluster experienced a strong and dynamic expansion as many new members joined its growing network. This influx of new companies and institutions further strengthened the cluster’s expertise, diversity, and innovative power. The cluster is now pleased to introduce these new members and highlight the diverse capabilities they bring, further reinforcing its […]

ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics

ariadne.ai Secures Invest BW Funding to Build “TumorTwin”: The First Digital Twin for Glioblastoma Powered by Morphometric Spatial Multi-Omics

HEIDELBERG, Germany – January 9, 2026 – ariadne.ai (Germany) GmbH today announced it has been awarded €518,000 in non-dilutive funding from the State of Baden- Württemberg (Invest BW) for its ambitious new project, TumorTwin. The project aims to revolutionize the treatment of Glioblastoma, one of the deadliest and most aggressive brain tumors, by creating a […]

AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline

AMGEN acquires Dark Blue Therapeutics, bolstering oncology pipeline

Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid Leukemia THOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced its acquisition of Dark Blue Therapeutics Ltd., a privately held biotechnology company based in the United Kingdom advancing first-in-class, small molecule-targeted protein degraders for oncology, in a transaction valued at up to $840 million.   The acquisition adds to Amgen’s […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp